Advanced Accelerator Applications – Neuroendocrine Tumors

Access Program Information

Advanced Accelerator Applications is currently pursuing marketing approval for
177Lu-DOTA0-Tyr3-Octreotate (Lutathera). This expanded access therapeutic protocol aims to
allow patients suffering from inoperable, somatostatin receptor positive, neuroendocrine
tumors, progressive under somatostatin analogue therapy to access the investigational
product, 177Lu-DOTA0-Tyr3-Octreotate (Lutathera), prior to its commercial availability.